Generic Drug Bill Would Limit Rx Patents To Drug Substance, Method Of Use
Executive Summary
Generic drug manufacturers would need to challenge only patents for the drug substance and the method of use under a bill by Sens. McCain (R-Ariz.) and Schumer (D-N.Y.)
You may also be interested in...
McCain/Schumer Generic Bill Would End 30-Month Stay Of Approval
The revised McCain/Schumer generic drug bill eliminates the automatic stay of approval under current patent challenge procedures.
McCain/Schumer Generic Bill Would End 30-Month Stay Of Approval
The revised McCain/Schumer generic drug bill eliminates the automatic stay of approval under current patent challenge procedures.
Generic Exclusivity "Incentive" Needs Review, FDA's Dickinson Says
The necessity of 180-day generic exclusivity should be reviewed, FDA Associate Counsel for Drugs Elizabeth Dickinson told the Food & Drug Law Institute conference on the Waxman/Hatch Act Dec. 11 in Washington, D.C.